Lilly Pulitzer is serving up a Valentine's Day partnership with Lele Sadoughi, the New York-based accessories brand. Marking their second collaboration, "Lilly Loves Lele" is a six-piece limited ...

Lawyers for the board that awards Pulitzer Prizes asked a Florida state court to pause the defamation lawsuit President Trump filed against board members in 2022 until Trump is no longer president.

The Pulitzer Prize board is asking a judge to hit pause on a defamation case President Donald Trump filed against it until his presidency is over, using Trump’s own legal arguments against him.

More than 50 years later, Gilliam hopes her play "The Bookstore," which is up for a Pulitzer Prize in the drama category, will elicit the same reaction. She began writing the play during the COVID ...

Eli Lilly (NYSE:LLY) is in advanced discussions to purchase cancer-focused biotech Scorpion Therapeutics for as much as $2.5 billion. FuboTV (NYSE:FUBO) and The Walt Disney Company (NYSE ...

Eli Lilly is reenergizing its attempt to challenge Novartis and Roche for a breast cancer market, kicking off the J.P. Morgan Healthcare Conference with a deal to buy Scorpion Therapeutics ...

Lawyers for the Pulitzer Prize Board have asked a judge to pause President Donald Trump's defamation lawsuit against its members, using the Republican's own legal arguments as part of his defense ...

For nearly a decade, Eli Lilly has been operating a global capability center (GCC) in Bengaluru, India. Now, with its business booming, the company is setting up a similar site 10 hours to the ...

Eli Lilly and venture capital firm Andreessen Horowitz (a16z) are joining forces to create a unique new fund dubbed the Biotech Ecosystem Venture Fund, backed by $500 million of Lilly’s capital.

SAN FRANCISCO — Eli Lilly said Monday it would acquire a cancer program from startup Scorpion Therapeutics in a deal worth up to $2.5 billion, as the Indianapolis company broadens its pipeline.

Eli Lilly & Co.’s fourth-quarter revenue fell short of analysts’ estimates as the drugmaker struggled to forecast demand for its popular weight-loss and diabetes shots for the second quarter ...